CSIMarket
 
Johnson and Johnson  (JNJ)
Other Ticker:  
 
 
Price: $156.1000 $3.03 1.979%
Day's High: $156.69 Week Perf: -2.02 %
Day's Low: $ 153.13 30 Day Perf: -2.74 %
Volume (M): 8,330 52 Wk High: $ 173.65
Volume (M$): $ 1,300,235 52 Wk Avg: $148.39
Open: $153.98 52 Wk Low: $109.16



 Market Capitalization (Millions $) 417,880
 Shares Outstanding (Millions) 2,677
 Employees 132,200
 Revenues (TTM) (Millions $) 82,584
 Net Income (TTM) (Millions $) 14,714
 Cash Flow (TTM) (Millions $) -3,320
 Capital Exp. (TTM) (Millions $) 3,347

Johnson And Johnson
Johnson & Johnson, is engaged in the manufacture and sale of a broad range of products in the health care field. Through over 200 operating companies, it conducts business in virtually all countries of the world. Johnson & Johnson's primary interest, both historically and currently, has been in products related to human health and well-being. Johnson & Johnson was organized in the State of New Jersey in 1887.


   Company Address: One Johnson & Johnson Plaza New Brunswick 8933 NJ
   Company Phone Number: 524-0400   Stock Exchange / Ticker: NYSE JNJ
   JNJ is expected to report next financial results on April 13, 2021. Next quarterly dividend pay out on March 09, 2021.


Customers Net Income grew by JNJ's customers Net margin grew to

19.82 %

4 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
PFE        2.69% 
MRK        0.7% 
LLY        0.99% 
BMY   -1.47%    
ALXN   -1.73%    
ABT   -2.11%    
• View Complete Report
   



Ampio Pharmaceuticals inc

Ampio Pharmaceuticals Inc announced fourth quarter of 2020 operating shortfall of $-3.911 millions

In the fourth quarter of 2020 Ampio Pharmaceuticals Inc loss increased of $-0.02 per share compared to $-0.01 a year ago and from $-0.02 per share from the previous quarter.

Ampio Pharmaceuticals Inc reported operating deficit of $-3.911 millions, in the fourth quarter of 2020, an improvement from the operating loss of $-7.145966 millions, realized in fourth quarter of 2019
Ampio Pharmaceuticals Inc reported net loss of $-15.89 millions and Sales of $0.00 millions for the fiscal year 2020.

Company has decreased loss per share to $-0.09 from $-0.14 in the previous fiscal year, while by 0 % from $0.00 millions a year ago.

Cowen inc

Cowen Inc announced fourth quarter of 2020 operating profit of $153.148 millions

Cowen Inc delivered very strong results in the fourth quarter of 2020, where Sales soared by 78.89% to $502.92 millions, while company's earnings per share soared by 2512.48 % to $3.00 per share, from the same quarter a year ago.

In contrast to the third quarter Sales improved by 29.71 % from $387.74 millions and eps more than doubled by 383.3 % from $0.62 per share.
In the fiscal year 2020, Cowen Inc reported Sales of $1.62 billions and net income of $207.06 millions.

Eps surged by 1145.61 % to $7.10 per share from $0.57 in the previous fiscal year, while Sales surged by 54.68 % from $1.05 billions a year ago.

Brown forman Corporation

Brown Forman Corporation announced most recent fiscal period operating profit of $281 millions

Brown Forman Corporation reported declining eps on increasing revenue in the most recent fiscal period, where Sales grew by 3.74% to $1.22 billions in comparison to $1.18 billions on a year-over-year basis, while earnings decreased by -6.25% to $0.45 per share, income per share was $0.48 in the same quarter a year ago.

In the previous quarter company realized Sales of $1.27 billions and bottom line of $0.50 per share.

Annovis Bio Inc

Logged a Loss, Topline Up Slightly

For the fourth quarter of 2020 Annovis Bio Inc lost money at $-0.25 per share, compared to results of $-0.87 per share a year ago quarter, In the previous quarter company realized $-0.15 per share.

from $0.00 millions in preceding quarter, increased losses from $-0.15 per share.
Annovis Bio Inc reported net loss of $-5.46 millions and Sales of $-0.03 millions for the fiscal year 2020.

Company recorded loss per share of $-0.87 compared to $1.73 in the previous fiscal year, while by -100 % from $4.28 billions a year ago.

Soleno Therapeutics Inc

Redemption of Losses but Revenues Unchanged

In the fourth quarter of 2020 earnings season Soleno Therapeutics Inc decreased loss of $-0.04 per share compared to $-0.35 a year ago and improved from $-0.11 per share from the previous quarter.

Soleno Therapeutics Inc reported operating shortfall of $-7.957 millions, in the fourth quarter of 2020 earnings season, a deterioration from the operating shortfall of $-6.752 millions, realized in fourth quarter of 2019
Soleno Therapeutics Inc reported net loss of $-24.64 millions and Sales of $0.00 millions for the fiscal year 2020.

Company has decreased loss per share to $-0.39 from $-0.90 in the previous fiscal year, while by 0 % from $0.00 millions a year ago.






 

Johnson And Johnson's Segments
 
PROCRIT
 Segment    3.06 % of total Revenue
RISPERDAL
 Segment    2.82 % of total Revenue
REMICADE
 Segment    18.37 % of total Revenue
VELCADE
 Segment    3.84 % of total Revenue
CONCERTA
 Segment    2.42 % of total Revenue
INVEGA
 Segment    1.8 % of total Revenue
Other
 Segment    9.08 % of total Revenue
Total Pharmaceutical
 Segment    44.67 % of total Revenue
Med. Dev. & Diag.
 Segment    35.75 % of total Revenue
Nutritionals
 Segment    5.48 % of total Revenue
Skin Care
 Segment    5.03 % of total Revenue
Total Consumer
 Segment    19.58 % of total Revenue
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Johnson And Johnson does not provide revenue guidance.

Earnings Outlook
Soleno Therapeutics Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion
United States 46.79 %
Europe 25.49 %
Asia Pacific 18.08 %
Other 9.63 %


       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

HMSY's Profile

Stock Price

HMSY's Financials

Business Description

Fundamentals

Charts & Quotes

HMSY's News

Suppliers

HMSY's Competitors

Customers & Markets

Economic Indicators

HMSY's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.  Free Stock Market News Feeds
   Copyright © 2021 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071